Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study of IMC-11F8 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: IMC-11F8

First Posted Date: 2010-03-17

Last Posted Date: 2017-02-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 15

Registration Number: NCT01088464

Locations: 🇯🇵
ImClone Investigational Site, Tokyo, Japan

A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults

Completed

Conditions: Pituitary Insufficiency
Growth Hormone Deficiency, Adult
Hypopituitarism

Interventions: Drug: Somatropin (rDNA origin)

First Posted Date: 2010-03-17

Last Posted Date: 2014-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10673

Registration Number: NCT01088399

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: ADP receptor inhibitors

First Posted Date: 2010-03-17

Last Posted Date: 2016-01-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12227

Registration Number: NCT01088503

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2010-03-16

Last Posted Date: 2014-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 69

Registration Number: NCT01087970

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States

A Study in Schizophrenia Patients

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: LY2140023
Drug: Risperidone

First Posted Date: 2010-03-15

Last Posted Date: 2012-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 880

Registration Number: NCT01086748

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yaroslavl, Russian Federation

A Study in Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-Fluorouracil

First Posted Date: 2010-03-05

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 187

Registration Number: NCT01081041

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico

Head and Neck Cancer Registry (LORHAN)

Completed

Conditions: Head and Neck Cancer

Interventions: Other: Therapy for head and neck cancer

First Posted Date: 2010-03-04

Last Posted Date: 2012-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26000

Registration Number: NCT01080313

Locations: 🇺🇸
Mednet Solutions, Minnetonka, Minnesota, United States

Study of FORTEO Use in Subjects in the Community Setting

Completed

Conditions: Osteoporosis

Interventions: Drug: FORTEO

First Posted Date: 2010-03-02

Last Posted Date: 2012-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4167

Registration Number: NCT01078805

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Colorado, United States

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2189265
Drug: Insulin Glargine
Drug: Metformin
Drug: Glimepiride

First Posted Date: 2010-02-25

Last Posted Date: 2015-01-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 810

Registration Number: NCT01075282

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan

The Cymbalta Pregnancy Registry

Completed

Conditions: Pregnancy

Interventions: Drug: duloxetine

First Posted Date: 2010-02-24

Last Posted Date: 2022-07-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 144

Registration Number: NCT01074151

Locations: 🇺🇸
The Cymbalta Pregnancy Registry Call Center, Wilmington, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy